The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1263 articles
Without improved prevention, cardiovascular disease rates in U.S. women could climb from 10.7% in 2020 to 14.4% in 2050, warns the American Heart Association. Rising obesity, diabetes, and high blood pressure are key drivers, especially among younger women and underserved groups. Experts call for urgent action on early detection and lifestyle changes.
New research shows that one night of total sleep deprivation significantly delays the glucagon-like peptide 1 (GLP-1) peak response to breakfast in healthy young men. This finding highlights how sleep loss disrupts key incretin hormones involved in glucose regulation and appetite control. Discover the study's design and what it means for metabolic health.
A new Japanese study reveals that three popular GLP-1 drugs—semaglutide, tirzepatide, and retatrutide—may offer hope for rare genetic obesity linked to MC4R deficiency. In mice models, these drugs led to significant weight loss despite faulty hunger signals. Experts discuss the potential and limitations for human treatment.
Tirzepatide doesn't just curb hunger—it may directly rev up fat-burning brown adipose tissue, according to a groundbreaking mouse study. Researchers separated its metabolic effects from simple calorie restriction, uncovering benefits for energy expenditure and blood glucose control. This could pave the way for more effective obesity therapies.
Grammy-nominated country singer Luke Combs revealed on The New York Times' Popcast why GLP-1 weight loss drugs aren't for him: he wants to 'beat myself' the hard way. Motivated by his wife and kids, Combs embraces the struggle over quick fixes amid lifelong weight battles. His story highlights the personal choice in pursuing metabolic health.
Pfizer is pushing forward on dual fronts: a major $495M deal for Ecnoglutide in China's booming GLP-1 market and full FDA approval for its BRAFTOVI regimen in metastatic colorectal cancer. Clinical data highlights 15.1% placebo-adjusted weight reduction and a 51% drop in mortality risk from the BREAKWATER study. These moves underscore Pfizer's strategy in metabolic and oncology therapeutics.
Health regulators have issued an urgent 'check now' warning to Mounjaro users after counterfeit 15mg KwikPens were dispensed at a Birmingham private clinic. While the fakes contain tirzepatide, unknown manufacturing raises infection risks. Patients are urged to verify their pens immediately.
Novo Nordisk is dramatically reducing prices for its blockbuster GLP-1 drugs, slashing Wegovy by 50% and Ozempic by 35% to $675 per month starting in January 2027. This move addresses calls for affordability from patients and payers facing high-deductible plans. Amid fierce competition from Eli Lilly's Mounjaro and Zepbound, these cuts could broaden access to these transformative medications.
Lasso, a food tech innovator, just launched Froobies and CronchClub—two snacks designed for GLP-1 users using proprietary SpinTech that weaves protein and fiber together. With clean ingredients, high macros, and craveable flavors, they address the nutritional demands of the GLP-1 era. Pre-order now and experience real snack innovation.
